

ISSUE @ A GLANCE



Modern prevention: genetic testing, vascular imaging, machine learning, and drug safety
T.F. Lüscher

1777

CardioPulse

The future of computers in cardiology: 'the connected patient'?

N. Bruining, R. Barendse, and P. Cummins

1781

Biotherapies and biomarkers for cardiovascular diseases

S. Roura, C. Gálvez-Montón, J. Lupón, and A. Bayes-Genis

1784

Obesity protects during cardiac surgery?

M. Nicholls

1786

NSAIDs and cardiac arrest

K.B. Sondergaard and G. Gislason

1788

Perseverance versus Pedigree

A. Kalra

1789

CURRENT OPINION

Assessing suspected angina: requiem for coronary computed tomography angiography or exercise electrocardiogram?

C.J.M. Vrints, R. Senior, F. Crea, and U. Sechtem

1792

Phosphate, pyrophosphate, and vascular calcification: a question of balance

R. Villa-Bellosta and J. Egido

1801

REVIEW



Prevention and epidemiology

Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges

B.A. Goldstein, A.M. Navar, and R.E. Carter

1805

CLINICAL RESEARCH

Prevention and epidemiology

Comparison of coronary artery calcification, carotid intima-media thickness and ankle-brachial index for predicting 10-year incident cardiovascular events in the general population


M.H. Geisel, M. Bauer, F. Hennig, B. Hoffmann, N. Lehmann, S. Möhlenkamp, K. Kröger, K. Kara, T. Müller, S. Moebus, R. Erbel, A. Scherag, K.-H. Jöckel, and A.A. Mahabadi; on behalf of the investigative group of the Heinz Nixdorf Recall study

1815

FAST TRACK CLINICAL RESEARCH



Basic science for the clinician



A novel but frequent variant in *LPA* KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction
S. Coassin, G. Erhart, H. Weissensteiner, M. Eca Guimarães de Araújo, C. Lamina, S. Schönherr, L. Forer, M. Haun, J.L. Losso, A. Köttgen, K. Schmidt, G. Utermann, A. Peters, C. Gieger, K. Strauch, A. Finkstedt, R. Bale, H. Zoller, B. Paulweber, K.-U. Eckardt, A. Hüttenhofer, L.A. Huber, and F. Kronenberg

1823

CLINICAL RESEARCH

Prevention and epidemiology

Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK

M. Kerr, R. Pears, Z. Miedzybrodzka, K. Haralambos, M. Cather, M. Watson, and S.E. Humphries

1832


Editorial

Can we afford not to screen for FH?

R.M. Stoekenbroek, J.J.P. Kastelein, and G.K. Hovingh

1840

(b)



Patients at risk

Celecoxib	3647	3400	2762	1770	901	296
naNSAID	3650	3502	2894	1829	939	304

Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT)

T.M. MacDonald, C.J. Hawkey, I. Ford, J.J.V. McMurray, J.M. Scheiman, J. Hallas, E. Findlay, D.E. Grobbee, F.D.R. Hobbs, S.H. Ralston, D.M. Reid, M.R. Walters, J. Webster, F. Ruschitzka, L.D. Ritchie, S. Perez-Gutthann, E. Connolly, N. Greenlaw, A. Wilson, L. Wei, and I.S. Mackenzie

1843

Editorial

Traditional NSAIDs and coxibs: is one better than the other?

D. Mukherjee

1851

CARDIOVASCULAR FLASHLIGHTS

Succinate dehydrogenase gene mutation with cardiac paraganglioma: multimodality imaging and pathological correlation

S. Romano, C. Fava, P. Minuz, and A. Farzaneh-Far

1853

Massive aortic valve thrombosis with free floating thrombus following transcatheter aortic valve replacement

J.A. Luetkens, H.H. Schild, and D.K. Thomas

1855

Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site
<https://academic.oup.com/eurheartj>



www.eurheartj.org